MU logo News Bureau University of Missouri About the News Bureau Contact Us Home / News Releases / 2009 MU Researchers Discover Target that Could Ease Spinal Muscular Atrophy SymptomsJanuary 08, 2009COLUMBIA, Mo. - There is no cure for spinal muscular atrophy (SMA), a genetic disorder that causes the weakening of muscles and is the leading genetic cause of infant death, but University of Missouri researchers have discovered a new therapeutic target that improves deteriorating skeletal muscle tissue caused by SMA. The new therapy enhanced muscle strength, improved gross motor skills and increased the lifespan in a SMA model. "This therapy does not directly target the disease-causing gene; instead it targets the pathways that affect muscle maintenance and growth," said Chris Lorson, investigator in the Christopher S. Bond Life Sciences Center and associate professor of veterinary pathobiology in the MU College of Veterinary Medicine. "We administered a particular protein, follistatin, to SMA mouse models to determine if enhanced muscle mass impacts the symptoms of SMA. After treatment, the mice had increased muscle mass, gross motor function improvement and an increase in average life span of 30 percent." With the therapy, MU researchers inhibited myostatin, a protein that limits muscle tissue growth. Myostatin activity can be reduced significantly by enabling several proteins that bind to myostatin, including follistatin. When myostatin is inhibited, muscle mass and strength increase. SMA is caused by the loss of survival motor neuron-1(SMN1). Humans have a nearly identical copy gene called SMN2. Because of a single molecular difference, SMN2 alone cannot compensate for the loss of SMN1. "While most work in the SMA field has logically focused on targeting the SMN2 gene, the results of this study suggest that skeletal muscle is a viable therapeutic target that may reduce the severity of some SMA symptoms," said Lorson, who also is the scientific director for FightSMA, a private spinal muscular atrophy research foundation in Richmond, Va. "Because follistatin does not alter the expression level of SMN protein, the most effective treatment would combine strategies that directly address the genetic defect in SMA as well as SMN-independent strategies that enhance skeletal muscle." The study, "Delivery of recombinant follistatin lessens disease severity in a mouse model of Spinal Muscular Atrophy," was published online in the December issue of Human Molecular Genetics. The research team also consisted of graduate students Frankie Rose and Virginia Mattis, and Hans Rindt, an assistant research professor. Recently, Lorson was awarded a $370,000 grant from the Muscular Dystrophy Association to continue his research on the role of muscle in SMA. University of Missouri |
|||||||||||||||||||||
| Related Spinal Muscular Atrophy Current Events and Spinal Muscular Atrophy News Articles Researchers identify drug candidate for treating spinal muscular atrophy A chemical cousin of the common antibiotic tetracycline might be useful in treating spinal muscular atrophy (SMA), a currently incurable disease that is the leading genetic cause of death in infants. ISU researchers find possible treatment for Spinal Muscular Atrophy Spinal Muscular Atrophy is the second-leading cause of infant mortality in the world. UCLA stem cells scientists make electrically active motor neurons from iPS cells Stem cells scientists at UCLA showed for the first time that human induced pluripotent stem (iPS) cells can be differentiated into electrically active motor neurons, a discovery that may aid in studying and treating neurological disorders. Patient-derived induced stem cells retain disease traits hen neurons started dying in Clive Svendsen's lab dishes, he couldn't have been more pleased. The dying cells - the same type lost in patients with the devastating neurological disease spinal muscular atrophy - confirmed that the University of Wisconsin-Madison stem cell biologist had recreated the hallmarks of a genetic disorder in the lab, using stem cells derived from a patient. Molecular Therapy for Spinal Muscular Atrophy Closer to Clinical Use Spinal muscular atrophy, a neurodegenerative disorder that causes the weakening of muscles, is the leading cause of infant death and occurs in 1 in 6,000 live births. Genetic test for spinal muscular atrophy should be offered to all couples, says the ACMG Carrier screening for spinal muscular atrophy (SMA)-a serious genetic disease affecting approximately 1 in 10,000 infants that causes progressive muscle weakness and death-should be made available to all families, according to a new practice guideline issued by the American College of Medical Genetics (ACMG). Penn researchers gain new insights on spinal muscular atrophy Researchers from the University of Pennsylvania School of Medicine discovered that the effect of a protein deficiency, which is the basis of the neuromuscular disease spinal muscular atrophy (SMA), is not restricted to motor nerve cells, suggesting that SMA is a more general disorder. Cold Spring Harbor Laboratory Scientists Devise Potential Approach To Treat Spinal Muscular Atrophy In the neuromuscular disease called spinal muscular atrophy, or SMA, a protein deficiency caused by a single gene mutation leads to serious damage in growing nerve cells and the muscles they control. CSHL shows correcting rna splicing may help treat spinal muscular atrophy RNA splicing antisense technology studied at Cold Spring Harbor Laboratory (CSHL) effectively corrected an mRNA splicing defect found in spinal muscular atrophy (SMA) patients, and is now ready to be tested in mouse models. Treatment extends survival in mouse model of spinal muscular atrophy Drug therapy can extend survival and improve movement in a mouse model of spinal muscular atrophy (SMA), new research shows. The study, carried out at the NIH's National Institute of Neurological Disorders and Stroke (NINDS), suggests that similar drugs might one day be useful for treating human SMA. More Spinal Muscular Atrophy Current Events and Spinal Muscular Atrophy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||